SciTech Development, LLC
P.O. Box 36927
Grosse Pointe Farms, MI 48236

Market Sector

- Specialty oncology pharmaceutical

Products

- ST-001: a multi-target nanoFenretinide cancer drug
- SciTech Delivery Platform (SDP)
- Patent protected

Stage

- Clinical-stage with Phase 1 clinical trials in process
- https://clinicaltrials.gov/study/NCT04234048

Intellectual Property

- Worldwide License
- U.S. patent # 8709379B2
- E.U. patent # 2013016

Leadership Team

- CEO - Earle Holsapple
- CFO - Andrew Stumpf
- CSA - Ralph Parchment
- COO - Lou Scarmoutzos
- DStD - Michael Burns
- DCA - Ali Moiin
- IR/BD- David Schaffer

Investment

Raised to Date

- $9mm

Second Financing Round

- Total Ask: $19mm
  - ◊ $3mm note
  - ◊ $16mm Series A to open Q2/2024

Use of Proceeds

- Enable continuity of Phase 1a/b accelerated clinical trials
- Drug manufacturing
- Operating capital
- Scale management team
- Prepare for filings toward commercialization efforts

Investor Relations Contact

David R. Schaffer

DRS@SciTechDevelopment.com
+1 (727) 278-8188 (US)

SciTech Development, LLC

A clinical-stage, specialty oncology pharmaceutical company

Revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer

ST-001 nanoFenretinide: Lead Drug Candidate in Clinical Trials

Through a combination of innovative science and advanced nanotechnology, SciTech has developed ST-001nanoFenretinide, a patented formulation that is in clinical trials for T-cell lymphomas (a form of non-Hodgkin lymphoma).

Problem: Low Drug Bioavailability Severely Limits Clinical Use

Many cancer drugs have low bioavailability (absorption) due to water insolubility. This results in sub-therapeutic dosing levels and insufficient amounts of the drug delivered to the cancer cells. Increasing the dose can lead to unacceptable toxicity levels and side effects. Fenretinide's low bioavailability presented challenges for use in cancer and remained unsolved - *until now*.

Solution: An Effective Delivery Platform and ST-001 nanoFenretinide

ST-001 is a nanoparticle combination of fenretinide and biocompatible phospholipids, allowing rapid infusion (IV) of high-dose fenretinide to solve bioavailability challenges, avoid triglyceride (or fatty) toxicity, and optimize therapeutic efficacy.

- Overcomes drug delivery and bioavailability challenges seen with fenretinide
- Safely achieves therapeutically effective dosing
- Avoids toxic side effects seen with other delivery systems and formulations
- Delivers a 6-fold higher formulation strength than conventional IV formulations
- Safely delivers at least a 15-fold higher concentration of fenretinide to target cancer cells than other reference formulations**
- Enables potential use in numerous other cancers types

ST-001 Clinical Trials

- Clinical trials involving several medical centers commenced December 2023
- FDA approved, accelerated Phase 1a/b clinical trial for T-cell lymphoma
- Institutional Review Board (IRB) approved
- Phase 1b for small cell lung cancer to commence after Phase 1a T-cell trial
- Successfully manufactured cGMP clinical supply of ST-001 with contract drug manufacturing partner

SDP: SciTech Nanoparticle Drug Delivery Platform

- Patented nanoparticle drug delivery platform (SDP) built to solve bioavailability and toxicity challenges
- Uses safe phospholipids to maintain or improve safety profiles
- May be utilized to increase SciTech's product pipeline in various other cancers
- May be used to formulate other similarly challenged therapeutic agents

SciTech Investment Highlights

- Completed $2.73mm convertible note round (CNR)
- Funds will be used to advance the accelerated Phase 1a portion of clinical trial for ST-001 in T-cell Lymphoma
- $3mm Convertible Note Round (CNR)
- $16mm Series A to open Q2/2024
- Funds will advance ST-001 through the completion of the Phase 1a/b trials and build infrastructure for the commercialization stage
- Value inflection data anticipated in Q3/4 2024

Commercialization Strategy

- Goal is to commercialize ST-001 in T-cell lymphomas and Small Cell Lung Cancer (SCLC) with the accelerated Phase 1a/b clinical trial strategy.
- Develop partnerships with pharma and biotech companies to expand their oncology pipeline, gain a foothold in targeted oncology domains, or utilize the SDP drug delivery platform for improved companion therapeutics.

***Source: NIH, Data is based on current fenretinide formulations*

Milestones and Achievements

- Closed CNR financing of $2.73mm, Q2/2023
- ST-001 drug manufacturing completed for trial supply
- Institutional Review Board (IRB) approved for patient recruitment
- Added 3 key medical advisors
- Orphan drug designation granted 2017 for cutaneous and peripheral T-cell lymphomas
- IND Received from the FDA in 2019 for T-cell Lymphomas
- ST-001 patent granted in 2013
- US Patent extension to 2030

Partners and Collaborators

- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Karmanos Cancer Institute
  Wayne State University, MI
- Ferndale Pharma Group
  Ferndale, MI
- Plough Manufacturing
  Memphis, TN
- BD/M Collective
  Henderson, NV

Clinical Sites

- University of Pittsburgh School of Medicine
- University of Southern California Keck School of Medicine
- Columbia University Medical Center
- Karmanos Cancer Center at Wayne State University
- Additional institutions in process

Law Firms

- Taft Law
- Wilson Sonsini Goodrich & Rosati

Bank

- First Citizens / SVB

For More Information:

- www.SciTechSDP.com
- www. SciTechDevelopment.com
  (for more in-depth science information)

Fenretinide as a Therapeutic Agent

The National Cancer Institute (NCI) saw the vast potential of fenretinide and funded its development. Fenretinide has been clinically tested and deemed safe in over 3,000+ patients. However, due to bioavailability issues of past formulations, high concentrations of fenretinide could not reach and kill the target cancer cells. SciTech led the effort to find the solution with its patented methods of nanoparticalization and phospholipids to solve fenretinide's bioavailability issue by developing SciTech's Delivery Platform (SDP) and ST-001 nanoFenretinide.

Multiple Mechanisms of Action

Fenretinide is a synthetic derivative of vitamin A (retinoid) that has been extensively studied for its potential anticancer properties. Several mechanisms of action have been proposed for inducing cancer cell death such as; the ability to inhibit the metabolism of retinoic acid, binds to multiple retinoid receptors, damages mitochondrial function, modulates cellular signaling pathways, and inhibits the formation of new blood vessels necessary for tumor growth and metastasis. In addition, fenretinide may "reactivate" the body's natural immune response and may be used as a complement to chemotherapy treatment, further enhancing ST-001's value.

A Large Target Market

The US market opportunity for T-cell lymphoma, small cell lung cancer and metastatic breast cancer is over $2B. ST-001 is anticipated to be efficacious in other lymphomas, lung, leukemia, colo-rectal, head & neck, ovarian, cervical, and pancreatic cancers. These additional indications plus the potential to use ST-001 as a combination therapy, will add significant revenue potential due to unmet clinical needs in oncology while increasing the market potential to over $5B+.



An Experienced Leadership Team

Earle Holsapple, CEO, President & Co-Founder; Director, Center for Cancer Economics, Technology Assessment, Innovation & Development (CETAID), Karmanos Cancer Institute; CEO/COO of six profitable, midsized corporations; Raised significant capital for 4 startups.

Ralph Parchment, Ph.D., Co-Founder and Chief Scientific Advisor; Pharmacologist; Director, Multi-Laboratory Research Program, Frederick National Laboratory for Cancer Research, Discovered ST-001 and SDP Drug Delivery Platform while at Karmanos Cancer Institute.

Louis Scarmoutzos, Ph.D., Chief Operations Officer; Consultant to National Institute of Health and the National Science Foundation commercialization programs, Drug development lead; Dual proficiency in science and business. Post-Doctoral Fellow in Chemistry/Chemical Biology at Harvard.

Ali Moiin, M.D., Director of Clinical Affairs; Board-certified dermatologist with extensive experience treating Cutaneous T-cell Lymphoma (CTCL) patients. Clinical Professor at Wayne State University, School of Medicine; Doctor of Medicine degree from University California, Davis.

Andrew Stumpf, MBA, Chief Financial Officer; Financial, accounting, and valuation advisory services to Fortune 500 and mid-market companies; Partner with Storm Lake Capital, VP for Stout Risius Ross Advisors, and auditor with Ernst & Young.

Michael Burns, Ph.D., MBA, Director Corporate and Strategic and Development; Former President and COO of Ferndale Pharma Group; Extensive pharmaceutical industry experience including product development, R&D, sales and marketing, licensing, and M&A.

David R. Schaffer, Director of Business Development and Investor Relations; Experience in global equity markets, investment banking, investor relations, and strategic advisory to public/private funds, most notably as Managing Director with Raymond James and previously with Advest.

Exceptional Medical and Strategic Advisory Board

Madeleine Duvic, M.D.; Deputy Department Chair, Dermatology at MD Anderson Cancer Center.

Larisa Geskin, M.D.; Director, Comprehensive Cutaneous Oncology Center at Columbia University.

Ajay Gopal, M.D.; Medical Director, Clinical Research and Hematology at Fred Hutchinson Cancer Center.

Tony Polverino, Ph.D.; Former Executive Director of Amgen, Former CSO of Kite Pharmaceuticals.

Bill Werkmeister, MBA; Partner, Harlem River Navy, Board of National Foundation for Cancer Research.

Ken Massey, Ph.D.; Senior Director of Venture Development at Wayne State University/Karmanos Cancer.